Clinical Trial
Comparison of 1 -testololactone (NSC-23759) and an estrogen-progestin combination (NSC-77622) in the treatment of metastatic breast cancer
- PMID: 4946009
Item in Clipboard
Clinical Trial
Comparison of 1 -testololactone (NSC-23759) and an estrogen-progestin combination (NSC-77622) in the treatment of metastatic breast cancer
Cancer Chemother Rep.
1970 Aug.
No abstract available
Similar articles
-
Teslac.Med Lett Drugs Ther. 1970 May 29;12(11):45-6. Med Lett Drugs Ther. 1970. PMID: 4935986 Clinical Trial. No abstract available.
-
[Hormone treatment of breast cancer in the advanced phase].Brux Med. 1968 Oct;48(10):665-9. Brux Med. 1968. PMID: 5757971 French. No abstract available.
-
Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.Cancer. 1969 Jan;23(1):109-12. doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1. Cancer. 1969. PMID: 4884063 Clinical Trial. No abstract available.
-
[Pure antiestrogen for treatment of advanced breast cancers].Nihon Rinsho. 2000 Apr;58 Suppl:334-9. Nihon Rinsho. 2000. PMID: 11026015 Review. Japanese. No abstract available.
-
Fulvestrant (Faslodex): current status in the therapy of breast cancer.Expert Rev Anticancer Ther. 2002 Apr;2(2):151-60. doi: 10.1586/14737140.2.2.151. Expert Rev Anticancer Ther. 2002. PMID: 12113237 Review.